Trials / Active Not Recruiting
Active Not RecruitingNCT04781192
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Phase I/II Clinical Trial of Regorafenib Plus Durvalumab (MEDI4736) in Patients With Chemo Refractory Advanced Biliary Tract Cancers
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\]) |
| DRUG | Regorafenib | Oral once per day, Days 1 - 21 every 28 days |
Timeline
- Start date
- 2022-03-22
- Primary completion
- 2025-11-12
- Completion
- 2026-12-01
- First posted
- 2021-03-04
- Last updated
- 2026-01-23
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04781192. Inclusion in this directory is not an endorsement.